IQM
1.7.2021 13:02:09 CEST | Business Wire | Press release
IQM Quantum Computers (IQM) expands its operations to Spain, creating a subsidiary in Bilbao. This operation has been supported by Basque local administration via Provincial Council of Bizkaia and Bilbao City Hall.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005046/en/
With its Spain operations, IQM aims to tap into another hotspot for quantum computing in addition to its Finland and Germany offices. IQM Spain will collaborate closely with the local research community, quantum experts from academia and the industry to build a vibrant Spanish and European quantum ecosystem. IQM with its international partner network will also connect the Spanish quantum ecosystem to the global quantum network.
“QUTIS Center in University of the Basque Country Bilbao has outstanding experience and experts in quantum computation and simulation, quantum control, quantum sensing and other areas. Today’s announcement signals our commitment to accelerate the success of our application-specific quantum computers, and aggressively develop quantum finance offerings for our customers worldwide,” said Jan Goetz, CEO at IQM. “Local Public Administration, via Beaz and Bilbao Ekintza, have been extremely supportive and are committed to attracting best talent and growth companies. We look forward to working with their team to grow our Co-Design offering from Spain and deliver it globally.”
The technical goal for this Spanish subsidiary is to create a quantum finance Co-Design hub that tightens the interaction between hardware and software to solve problems in finance. In particular, IQM Spain will develop an application-specific approach where quantum software integrates closely with a suitably designed quantum hardware with novel quantum architectures. Combined with IQM's hardware experts and go-to market teams in Finland and Germany, IQM will be able to deliver this offering to global customers. This approach accelerates the development of useful quantum solutions for specialized financial applications and will establish Spain and Europe as the leaders for quantum finance.
Last year, IQM had also entered into a research agreement with the University of the Basque Country (UPV/EHU) in Bilbao, a collaboration led by Dr. Jorge Casanova (Ramón y Cajal and Ikerbasque researcher at UPV/EHU) and includes Dr. Mikel Sanz (Ikerbasque Researcher at UPV/EHU) and Prof. Xi Chen (Professor at Shanghai University and Ramon y Cajal researcher at UPV/EHU).
Ms. Olatz Goitia, General Manager of Beaz, said, “We work to turn the territory into an innovation hub of international reference, and to this end, the retention and attraction of talent and entrepreneurship and companies like IQM is key.”
Mr. Javier Garcinuño Zabala, General Manager of Bilbao Ekintza, said, “We’re pleased to see European growth companies like IQM start their Spanish operations in Bilbao. Our BIG Bilbao entrepreneurship centre will support their local operations and Bilbao Ekintza will also collaborate with IQM on joint projects in Bilbao’s strategic economic sectors.”
About Beaz:
Beaz is a public company of the Provincial Council of Bizkaia whose objective is to support companies and entrepreneurs in their efforts to create new projects, innovate and internationalize. A goal that is in line with that of the Regional Department of Economic Promotion, to which Beaz reports directly: to contribute to the growth of economic activity and the creation of qualified employment.
About Bilbao Ekintza:
Bilbao Ekintza is a public company of Bilbao City Hall that develops the municipal powers in the field of economic development, promotion of Bilbao and its events as a tourist destination and business promotion, both from the point of view of the attraction, creation and growth of companies and the improvement of opportunities for access to employment.
https://www.bilbaoekintza.eus/en
About IQM Quantum Computers:
IQM is the European leader in superconducting quantum computers, headquartered in Espoo, Finland. Since its inception in 2018, IQM has grown to 110+ employees and established a subsidiary in Munich, Germany, to lead the Co-Design approach.
IQM delivers on-premises quantum computers for research laboratories and supercomputing centers and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific Co-Design approach.
IQM is building Finland’s first commercial quantum computer with VTT, and an IQM-led consortium was awarded € 12.4 Million in February 2021 to commercialize application-specific quantum processors by the German Ministry of Education and Research.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom